The TRAP clinical study (Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin; ClinicalTrials.gov number NCT02029690, registered December 16, 2013) investigated arginine deprivation combination chemotherapy (pegargiminase with pemetrexed and cisplatin [ADIPemCis]) in patients with ASS1-deficient MPM and nonsquamous NSCLC.13 This evidence concerns the gene ASS1 and non-small cell lung carcinoma.